.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Identify first generic entrants
  • Set up watchlists for daily email updates

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Accenture
QuintilesIMS
Dow
Johnson and Johnson
Colorcon
McKesson
US Department of Justice
Cerilliant
Medtronic

Generated: June 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,958,951

« Back to Dashboard

Which drugs does patent 5,958,951 protect, and when does it expire?


Patent 5,958,951 protects GABITRIL and is included in one NDA. There have been two Paragraph IV challenges on Gabitril.

This patent has twenty-four patent family members in twenty-one countries.

Summary for Patent: 5,958,951

Title: Modified form of the R(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride
Abstract:The present invention provides R(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride in its pure and stable anhydrous form.
Inventor(s): Ahrndt; Preben (.O slashed.lstykke, DK), Petersen; Henning B.o slashed.rge (Lyngby, DK), Chang; Vincent H. (Lake Forest, IL), Allen; Kimberly Ann (Silver Lake, WI), Cain; Michael H. (Grayslake, IL)
Assignee: Novo Nordiskials (Bagsvoerd, DK)
Application Number:08/872,380
Patent Claim Types:
see list of patent claims
Compound; Process; Formulation; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Cephalon
GABITRIL
tiagabine hydrochloride
TABLET;ORAL020646-005Apr 16, 1999ABRXYesNo5,958,951► Subscribe
Cephalon
GABITRIL
tiagabine hydrochloride
TABLET;ORAL020646-001Sep 30, 1997ABRXYesYes5,958,951► Subscribe
Cephalon
GABITRIL
tiagabine hydrochloride
TABLET;ORAL020646-002Sep 30, 1997RXYesNo5,958,951► Subscribe
Cephalon
GABITRIL
tiagabine hydrochloride
TABLET;ORAL020646-003Sep 30, 1997RXYesNo5,958,951► Subscribe
Cephalon
GABITRIL
tiagabine hydrochloride
TABLET;ORAL020646-004Sep 30, 1997DISCNNoNo5,958,951► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,958,951

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark0661/96Jun 14, 1996

International Patent Family for Patent: 5,958,951

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina008236► Subscribe
Austria223405► Subscribe
Australia3165397► Subscribe
Australia723267► Subscribe
Brazil9709725► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
AstraZeneca
Queensland Health
Daiichi Sankyo
McKinsey
Citi
Merck
Harvard Business School
Johnson and Johnson
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot